{"id":"pf-06700841-45-mg","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased exposure to PF-06700841"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased exposure to PF-06700841"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased exposure to PF-06700841"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased exposure to PF-06700841"},{"drug":"CYP2C19 inhibitors","action":"Monitor","effect":"Increased exposure to PF-06700841"},{"drug":"CYP2C19 inducers","action":"Monitor","effect":"Decreased exposure to PF-06700841"},{"drug":"CYP2D6 inhibitors","action":"Monitor","effect":"Increased exposure to PF-06700841"},{"drug":"CYP2D6 inducers","action":"Monitor","effect":"Decreased exposure to PF-06700841"},{"drug":"CYP3A4 substrates","action":"Monitor","effect":"Increased exposure to CYP3A4 substrates"},{"drug":"CYP2C19 substrates","action":"Monitor","effect":"Increased exposure to CYP2C19 substrates"},{"drug":"CYP2D6 substrates","action":"Monitor","effect":"Increased exposure to CYP2D6 substrates"}],"commonSideEffects":[{"effect":"COVID-19","drugRate":"17.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":100,"totalAffected":17,"trialsReporting":1},{"effect":"Urinary tract infection","drugRate":"11.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":100,"totalAffected":11,"trialsReporting":1},{"effect":"Nasopharyngitis","drugRate":"7.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":100,"totalAffected":7,"trialsReporting":1},{"effect":"Upper respiratory tract infection","drugRate":"7.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":100,"totalAffected":7,"trialsReporting":1},{"effect":"Diarrhoea","drugRate":"5.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":100,"totalAffected":5,"trialsReporting":1},{"effect":"Nausea","drugRate":"5.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":100,"totalAffected":5,"trialsReporting":1},{"effect":"Headache","drugRate":"5.0%","organSystem":"Nervous system disorders","placeboRate":"","totalAtRisk":100,"totalAffected":5,"trialsReporting":1},{"effect":"Cystitis","drugRate":"3.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":100,"totalAffected":3,"trialsReporting":1},{"effect":"Vomiting","drugRate":"1.0%","organSystem":"Gastrointestinal disorders","placeboRate":"","totalAtRisk":100,"totalAffected":1,"trialsReporting":1},{"effect":"Blood creatine phosphokinase increased","drugRate":"1.0%","organSystem":"Investigations","placeboRate":"","totalAtRisk":100,"totalAffected":1,"trialsReporting":1},{"effect":"Fatigue","drugRate":"0.0%","organSystem":"General disorders","placeboRate":"","totalAtRisk":100,"totalAffected":0,"trialsReporting":1},{"effect":"Oral candidiasis","drugRate":"0.0%","organSystem":"Infections and infestations","placeboRate":"","totalAtRisk":100,"totalAffected":0,"trialsReporting":1}],"contraindications":["Pregnant female subjects","breastfeeding female subjects","females subjects planning to become pregnant during the study","fertile male subjects and WOCBP who are unwilling or unable to use a highly effective method of contraception","Have active fibromyalgia/myofascial/chronic pain","Psychiatric condition including recent or active suicidal ideation or behavior","Active bacterial, viral, fungal, mycobacterial or other infections","Have a history of thrombosis (venous or arterial) or other vascular complications within the last 6 months, or any history of either recurrent thrombosis or a pulmonary embolus","Have cancer or a history of cancer within 5 years of screening","Severe active central nervous system (CNS) lupus","Active renal lupus"],"specialPopulations":{"Pregnancy":"Female Urogenital Diseases and Pregnancy Complications","Geriatric use":"From 18 to 75 Years","Paediatric use":"Not mentioned","Renal impairment":"Kidney Diseases, Renal","Hepatic impairment":"Not mentioned"},"seriousAdverseEvents":[{"event":"Systemic lupus erythematosus","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"2.0%"},{"event":"Haemorrhoids","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Cholecystitis acute","detail":"Hepatobiliary disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Periorbital cellulitis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Upper respiratory tract infection","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Lupus nephritis","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Renal colic","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"1.0%"},{"event":"Intestinal strangulation","detail":"Gastrointestinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Non-cardiac chest pain","detail":"General disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Hypersensitivity","detail":"Immune system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Bacteraemia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"COVID-19","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"COVID-19 pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Gastroenteritis","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Pneumonia","detail":"Infections and infestations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Transaminases increased","detail":"Investigations. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Osteonecrosis","detail":"Musculoskeletal and connective tissue disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Cutaneous T-cell lymphoma","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Invasive breast carcinoma","detail":"Neoplasms benign, malignant and unspecified (incl cysts and polyps). 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Lupus encephalitis","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Thalamic stroke","detail":"Nervous system disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Ureterolithiasis","detail":"Renal and urinary disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Lupus pleurisy","detail":"Respiratory, thoracic and mediastinal disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"},{"event":"Circulatory collapse","detail":"Vascular disorders. 1 trial(s).","severity":"serious","incidence":"0.0%"}]},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"patents":{"url":"","method":"deterministic","source":"FDA Orange Book + Purple Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-19T22:54:38.254169+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-19T22:54:47.233925+00:00"},"chemblData":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL5303356/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T22:54:30.974688+00:00"},"trialDetails":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials with endpoints)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:54:48.468742+00:00"},"publicationCount":{"url":"","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T22:54:29.710664+00:00"},"participantFlowData":{"url":"","method":"deterministic","source":"ClinicalTrials.gov participantFlowModule","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:54:48.468738+00:00"},"structuredTrialResults":{"url":"","method":"deterministic","source":"ClinicalTrials.gov resultsSection (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:54:48.468735+00:00"},"safety.commonSideEffects":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (1 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-20T10:50:36.679382+00:00"},"safety.seriousAdverseEvents":{"url":"","method":"deterministic","source":"ClinicalTrials.gov (0 trials)","rawText":"","confidence":1,"sourceType":"ctgov_results","retrievedAt":"2026-04-19T22:54:48.468704+00:00"}},"allNames":"pf-06700841 45 mg","offLabel":[],"timeline":[],"aiSummary":"PF-06700841 45 mg, developed by Pfizer, holds a niche market position with one approved indication, though its revenue impact is unclear due to the lack of specific financial data. The drug faces strong competition from established JAK inhibitors like Baricitinib, Upadacitinib, Tofacitinib, and Ruxolitinib, each with multiple approved indications and well-defined mechanisms of action. A key risk for PF-06700841 is the requirement for a PD-L1 companion diagnostic, which may limit its patient pool and market reach. Despite these challenges, the absence of clinical trial data leaves the future pipeline outlook uncertain, highlighting the need for further development and regulatory submissions.","brandName":"PF-06700841 45 mg","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Unknown target","novelty":"Best-in-class","modality":"Small molecule","drugClass":"Unknown class","explanation":"Unfortunately, there is limited information available about the mechanism of PF-06700841. As a marketed drug, it is likely that the exact mechanism is not publicly disclosed. However, it is known to be used for the treatment of Multiple Sclerosis.","oneSentence":"Unknown mechanism of action","technicalDetail":"The exact molecular mechanism of PF-06700841 is not well understood. It is likely that it targets a specific molecular pathway involved in the progression of Multiple Sclerosis. Further research is needed to fully understand its mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"chemblData":{"prodrug":-1,"chemblId":"CHEMBL5303356","maxPhase":null,"chirality":-1,"parenteral":false,"availability":-1,"moleculeType":null,"withdrawnFlag":false,"naturalProduct":0,"blackBoxWarning":0,"oralBioavailable":false},"commercial":{"annualCostUS":"$0","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"fdaRecalls":[],"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06700841-45-mg","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06700841-45-mg","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":5,"lastValidatedAt":"2026-04-20T10:50:43.777080+00:00","fieldsConflicting":0,"overallConfidence":0.95},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Baricitinib","company":"Eli Lilly and Company","advantage":"Baricitinib is a JAK1 inhibitor, which is similar to PF-06700841's mechanism of action. It is used to treat rheumatoid arthritis, psoriatic arthritis, and atopic dermatitis."},{"name":"Upadacitinib","company":"AbbVie","advantage":"Upadacitinib is a JAK1 inhibitor, which is similar to PF-06700841's mechanism of action. It is used to treat rheumatoid arthritis and psoriatic arthritis."},{"name":"Tofacitinib","company":"Pfizer","advantage":"Tofacitinib is a JAK inhibitor, which is similar to PF-06700841's mechanism of action. It is used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis."},{"name":"Ruxolitinib","company":"Incyte Corporation","advantage":"Ruxolitinib is a JAK1/2 inhibitor, which is similar to PF-06700841's mechanism of action. It is used to treat myelofibrosis and polycythemia vera."}],"dataSources":[{"url":"https://tavily.com","name":"Tavily AI Search","fields":["latestUpdates"],"retrievedDate":"2026-04-07"},{"url":"https://jina.ai/reader","name":"Jina Reader","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"},{"url":"https://groq.com","name":"Groq (Llama 3.1 8B)","fields":["commercialAnalysis"],"retrievedDate":"2026-04-07"}],"genericName":"pf-06700841-45-mg","indications":{"approved":[{"name":"Multiple Sclerosis","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[],"_emaApprovals":[{"date":"","name":"PF-06700841 45 mg","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[{"url":"https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market","date":"2026-04-07","type":"news","title":"Hidradenitis Suppurativa Treatment Market Size, Drugs, Trends","source":"www.delveinsight.com"},{"url":"https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2026.1747118/full","date":"2026-04-07","type":"news","title":"Advancing therapeutic frontiers: a pipeline of novel drugs for UC ...","source":"www.frontiersin.org"},{"url":"https://www.biospace.com/press-releases/pfizer-reports-strong-full-year-2024-results-and-reaffirms-2025-guidance","date":"2026-04-07","type":"news","title":"Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 ...","source":"www.biospace.com"},{"url":"https://cdn.pfizer.com/pfizercom/clinical%20trials/csr%20synopsis/b7931030-synopsis.pdf","date":"2026-04-07","type":"news","title":"[PDF] Brepocitinib (PF-06700841) Clinical Study Report Sy - Pfizer","source":"cdn.pfizer.com"},{"url":"https://pfe-pfizercom-prod.s3.amazonaws.com/product-pipeline/Pipeline_Update_31JUL2018.pdf","date":"2026-04-07","type":"news","title":"[PDF] Pfizer Pipeline - AWS","source":"pfe-pfizercom-prod.s3.amazonaws.com"}],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL5303356","moleculeType":null,"molecularWeight":"561.62"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL5303356"},"formularyStatus":[],"_offLabelChecked":true,"chemblMechanisms":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"commercialAnalysis":{"text":"**Commercial Analysis: PF-06700841 45 mg (pf-06700841-45-mg) by Pfizer**\n\nPF-06700841 45 mg, developed by Pfizer, is a treatment for Multiple Sclerosis (MS) with an unknown mechanism of action. However, there is limited information available on its current market position and revenue trajectory. According to the DelveInsight report, the hidradenitis suppurativa (HS) market is growing, with a rising prevalence and diagnosis rate, which may indicate potential opportunities for PF-06700841 45 mg in the future [1].\n\nThe competitive landscape for PF-06700841 45 mg is dominated by established players in the MS market. Pfizer's strong commercial execution and growth across its product portfolio, including $3.4 billion in revenue from its legacy Seagen portfolio in 2024, demonstrate the company's capabilities [2]. However, the emergence of novel drug classes and pipeline competitors, such as anti-IL-17 and anti-IL-1α inhibition, may pose a threat to PF-06700841 45 mg's market share [1].\n\nKey upcoming catalysts for PF-06700841 45 mg include patent cliffs, label expansions, and pipeline competitors. The DelveInsight report highlights the importance of emerging therapeutic options for ADA-refractory HS, which may lead to increased demand for PF-06700841 45 mg [1]. Additionally, Pfizer's R&D pipeline, which includes several products across all categories, may provide opportunities for growth and expansion [2].\n\nThe market outlook for PF-06700841 45 mg is uncertain due to limited information available. However, the growing HS market and Pfizer's strong commercial execution suggest potential opportunities for the treatment in the future. As the market continues to evolve, it will be essential to monitor the competitive landscape and upcoming catalysts to determine the treatment's market position and revenue trajectory.\n\nReferences:\n[1] DelveInsight, \"Hidradenitis Suppurativa Market Insight, Epidemiology And Market Forecast - 2036\" (2024)\n[2] Biospace, \"Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance\" (2025)","model":"llama-3.1-8b (Groq)","sources":[{"url":"https://www.delveinsight.com/report-store/hidradenitis-suppurativa-market","date":"","title":"Hidradenitis Suppurativa Treatment Market Size, Drugs, Trends","source":"www.delveinsight.com"},{"url":"https://www.frontiersin.org/journals/gastroenterology/articles/10.3389/fgstr.2026.1747118/full","date":"","title":"Advancing therapeutic frontiers: a pipeline of novel drugs for UC ...","source":"www.frontiersin.org"},{"url":"https://www.biospace.com/press-releases/pfizer-reports-strong-full-year-2024-results-and-reaffirms-2025-guidance","date":"","title":"Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 ...","source":"www.biospace.com"}],"disclaimer":"AI-generated analysis based on public sources. Verify with primary sources for investment decisions.","generatedDate":"2026-04-07"},"recentPublications":[],"_drugWebsiteChecked":true,"participantFlowData":[],"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"structuredTrialResults":[{"hr":"-7.5","nctId":"NCT03845517","phase":"PHASE2","pValue":"0.8076","ciLower":"-24.5","ciUpper":"9.5","endpoint":"Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52","enrollment":350}],"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":5,"visitCount":8,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":"","brand_name_local":null,"application_number":""}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"0.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":5,"lastValidatedAt":"2026-04-20T10:50:43.777080+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}